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In this article, the following errors were made while processing the article:

On page 1, the correct affiliation of the author Hongming Pan is "Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China"

On page 3, heading *Results*, sub-heading *Patient demographics and disposition*, line 11, the correct sentence reads as: "All patients were Asian, the majority with moderately to poorly differentiated HCC, with a mean age of 55.6 years, 89% were men, 53% had an ECOG performance status of 0, and distant metastases were present in 39% of patients (Table 1)."

On page 4, heading *Results*, sub-heading *Safety*, line 2, the correct sentence reads as: "The most common (\>30%) AEs, regardless of causality, were nausea (42%), vomiting (37%), diarrhea (34%), aspartate transaminase (AST) increased, and decreased appetite (both 32%, Table 2)."

The online version of the paper has been corrected.
